The Tandem Meetings I Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR are the combined annual meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR). Administrators, clinicians, data manager / clinical research professionals, fellows-in-training, investigators, laboratory technicians, MD/PhDs, nurses, nurse practitioners, pharmacists, physician assistants, and other allied health professional attendees benefit from a full scientific program that addresses the most timely issues in hematopoietic cell transplantation and cellular therapy.

View all videos

The 2022 Tandem Meetings

The Tandem Meetings I Transplantation & Cellular Therapy Meetings

23–26 April 2022 | Salt Lake City, UT

VJHemOnc @VJHemOnc·

📣 Next week, we will be interviewing leading experts in myeloproliferative neoplasms at the third annual Texas MPN Workshop.

Here's what you can look forward to on day one of the program!

@mpdrc #TXMPN22 #MPNsm #HemOnc

Reply on Twitter 1559585808549560321 Retweet on Twitter 15595858085495603211 Like on Twitter 15595858085495603211 View Tweet 1559585808549560321

VJHemOnc @VJHemOnc·

We spoke with @MinnemaMonique at #EHA2022, who shared some interesting insights into various bispecific antibodies emerging for the treatment of multiple myeloma.

Watch here:

👉http://ow.ly/FJPI50Kk0XP👈

@EHA_Hematology #MMsm #HemOnc #ImmunoOnc

Reply on Twitter 1559450286762205184 Retweet on Twitter 15594502867622051841 Like on Twitter 15594502867622051841 View Tweet 1559450286762205184

VJHemOnc @VJHemOnc·

Learn more about the importance of circulating tumor DNA in patients with primary CNS lymphoma in our exclusive interview with Won Seog Kim (@SKKGSB):

🎥: http://ow.ly/vHO250Kk0A6

@EHA_Hematology #HemOnc #LymSM #EHA2022

Reply on Twitter 1559239139610038275 Retweet on Twitter 15592391396100382753 Like on Twitter 15592391396100382757 View Tweet 1559239139610038275

Retweet on Twitter VJHemOnc Retweeted

Rakesh Popat @DrRakeshPopat·

Age-standardized rates of incidence of myeloma worldwide
https://bmccancer.biomedcentral.com/articles/10.1186/s12885-021-08280-y
#mmsm

Reply on Twitter 1558940357605425153 Retweet on Twitter 155894035760542515310 Like on Twitter 155894035760542515324 View Tweet 1558940357605425153

VJHemOnc @VJHemOnc·

Learn more about the importance of genomic testing in CLL w/ leading experts in our feature, covering:

➡️ the definition of high-risk disease
➡️ the role of genomic testing in prognosis
➡️ TP53 testing & more!

👉http://ow.ly/Yr8o50K4aiw👈

#CLLsm #LeuSM #HemOnc

Reply on Twitter 1559087938297905154 Retweet on Twitter 15590879382979051541 Like on Twitter 15590879382979051542 View Tweet 1559087938297905154

The 2022 Tandem Meetings

The Tandem Meetings I Transplantation & Cellular Therapy Meetings

23–26 April 2022 | Salt Lake City, UT

The Tandem Meetings I Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR are the combined annual meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR). Administrators, clinicians, data manager / clinical research professionals, fellows-in-training, investigators, laboratory technicians, MD/PhDs, nurses, nurse practitioners, pharmacists, physician assistants, and other allied health professional attendees benefit from a full scientific program that addresses the most timely issues in hematopoietic cell transplantation and cellular therapy.

View all videos

VJHemOnc @VJHemOnc·

📣 Next week, we will be interviewing leading experts in myeloproliferative neoplasms at the third annual Texas MPN Workshop.

Here's what you can look forward to on day one of the program!

@mpdrc #TXMPN22 #MPNsm #HemOnc

Reply on Twitter 1559585808549560321 Retweet on Twitter 15595858085495603211 Like on Twitter 15595858085495603211 View Tweet 1559585808549560321

VJHemOnc @VJHemOnc·

We spoke with @MinnemaMonique at #EHA2022, who shared some interesting insights into various bispecific antibodies emerging for the treatment of multiple myeloma.

Watch here:

👉http://ow.ly/FJPI50Kk0XP👈

@EHA_Hematology #MMsm #HemOnc #ImmunoOnc

Reply on Twitter 1559450286762205184 Retweet on Twitter 15594502867622051841 Like on Twitter 15594502867622051841 View Tweet 1559450286762205184

VJHemOnc @VJHemOnc·

Learn more about the importance of circulating tumor DNA in patients with primary CNS lymphoma in our exclusive interview with Won Seog Kim (@SKKGSB):

🎥: http://ow.ly/vHO250Kk0A6

@EHA_Hematology #HemOnc #LymSM #EHA2022

Reply on Twitter 1559239139610038275 Retweet on Twitter 15592391396100382753 Like on Twitter 15592391396100382757 View Tweet 1559239139610038275

Retweet on Twitter VJHemOnc Retweeted

Rakesh Popat @DrRakeshPopat·

Age-standardized rates of incidence of myeloma worldwide
https://bmccancer.biomedcentral.com/articles/10.1186/s12885-021-08280-y
#mmsm

Reply on Twitter 1558940357605425153 Retweet on Twitter 155894035760542515310 Like on Twitter 155894035760542515324 View Tweet 1558940357605425153

VJHemOnc @VJHemOnc·

Learn more about the importance of genomic testing in CLL w/ leading experts in our feature, covering:

➡️ the definition of high-risk disease
➡️ the role of genomic testing in prognosis
➡️ TP53 testing & more!

👉http://ow.ly/Yr8o50K4aiw👈

#CLLsm #LeuSM #HemOnc

Reply on Twitter 1559087938297905154 Retweet on Twitter 15590879382979051541 Like on Twitter 15590879382979051542 View Tweet 1559087938297905154

CAR-T therapy vs autologous transplantation in R/R DLBCL

Anna Sureda • 25 Apr 2022

Optimizing lymphodepletion chemotherapy in CAR-T therapy recipients

Muhammad Bilal Abid • 23 Apr 2022

Use of belimumab for prophylaxis of chronic GvHD

Iskra Pusic • 24 Apr 2022

Universal CAR-T therapy for T-ALL

John DiPersio • 23 Apr 2022

Omidubicel vs standard umbilical cord transplantation

Usama Gergis • 24 Apr 2022

Repurposing drugs for the treatment of acute GvHD

Shernan Holtan • 25 Apr 2022

The role of post-transplant maintenance therapy in AML

Firas El Chaer • 23 Apr 2022

AlloHSCT for R/R LBCL after CAR-T therapy failure

Joanna Zurko • 14 Apr 2022

Interim analysis of TRANSFORM: liso-cel vs SOC in high-risk R/R LBCL

Manali Kamdar • 27 Apr 2022

Feasibility of outpatient CAR-T therapy for LBCL

Craig W. Freyer • 25 Apr 2022

Impact of corticosteroids, tocilizumab or filgrastim on the outcomes of CAR-T therapy recipients

Poorva Bindal • 26 Apr 2022

Approval of axi-cel in second-line for R/R LBCL & label update

Evandro Bezerra • 23 Apr 2022

Targeting TAMs in follicular lymphoma

Paolo Strati • 23 Apr 2022

Bispecific anti-CD20, anti-CD19 CAR-Ts for R/R NHL

Nirav Niranjan Shah • 23 Apr 2022

CD30-directed CAR-Ts co-expressing CCR4 in R/R HL and CD30+ CTCL

Natalie Grover • 28 Apr 2022

Current indications for the use of brentuximab vedotin in Hodgkin lymphoma

Anna Sureda • 25 Apr 2022

Latest advances in CAR-T for multiple myeloma: cilta-cel & new CAR-T platforms

Mahmoud Gaballa • 22 Apr 2022

Unmet needs for extramedullary disease in multiple myeloma

Radhika Bansal • 11 Apr 2022

Benefits of beti-cel gene therapy for transfusion-dependent β-thalassemia

Andreas Kulozik • 24 Apr 2022

Tab-cel for solid organ or allogeneic transplant recipients with EBV-PTLD

Susan Prockop • 23 Apr 2022

Outcomes of alloHSCT in TP53-mutated AML and MDS

Muhammad Umair Mushtaq • 25 Apr 2022

The role of post-transplant maintenance therapy in AML

Firas El Chaer • 23 Apr 2022

Monoclonal antibodies for the treatment of adult ALL

Usman Ali Akbar • 19 Apr 2022

Universal CAR-T therapy for T-ALL

John DiPersio • 23 Apr 2022